CODA Biotherapeutics, Inc.

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s

Prescription drug user fee reauthorization negotiations are nearly complete, as final touches are being made to commitments for the program’s next five years. Talks have been ongoing since 15 Septembe

Technology transfer from universities and other non-profit research institutions to private sector firms is core to the modern biopharma industry, but before the enactment of the Bayh-Dole Act in 1980

Venture capital investment in biopharmaceutical companies has been on the decline in 2019, but one segment of the industry has seen a big rise in VC funding – cell and gene therapy companies. A recent